
zzso agents zzso increase red blood cell zzso production by zzso the zzso zzso on zzso zzso zzso zzso are approved in the United States and Europe for treating zzso in cancer patients receiving zzso zzso safety issues include zzso events and there have been concerns about disease progression and/or mortality in cancer zzso This educational supplement paper is based on two recently published zzso We review both clinical trial data on zzso and disease progression and zzso data on how zzso could affect zzso zzso We conclude that zzso may have little effect on disease progression in chemotherapy patients, and zzso data indicate a direct or indirect effect of zzso on zzso growth is not strongly zzso We also zzso the mechanisms and clinical consequences of iron zzso and zzso in cancer zzso zzso clinical trials have shown superior efficacy of zzso iron over oral or no iron in reducing blood zzso increasing zzso and improving quality of life in zzso zzso advanced cancer zzso Furthermore, zzso iron without additional zzso should be evaluated as potential treatment in patients with zzso zzso at recommended doses, zzso iron is well zzso particularly compared with oral iron, but caution should be used in some specific zzso 

